Are HMG-CoA reductase inhibitors underutilized in dialysis patients?

Related Experiment Video

Updated: Sep 26, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Stephen L Seliger, Catherine O Stehman-Breen

    Seminars in Dialysis
    |May 20, 2003
    PubMed

    Insights

    Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, may reduce cardiovascular disease (CVD) risk in dialysis patients. Further research is needed to confirm their safety and efficacy in this population.

    Area of Science:

    • Nephrology
    • Cardiology
    • Pharmacology

    Background:

    • Patients with end-stage renal disease (ESRD) on dialysis face significantly higher cardiovascular disease (CVD) rates than the general population.
    • 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) effectively lower cardiovascular risk in non-dialysis patients, but their role in ESRD populations is less understood.

    Discussion:

    • This review examines the link between dyslipidemia and cardiac disease in dialysis patients.
    • Potential mechanisms for statin-mediated cardioprotection in ESRD are explored.
    • Prior clinical studies on statin use in dialysis patients are analyzed for safety and efficacy.

    Key Insights:

    • Current evidence on statin therapy in dialysis patients requires careful evaluation.
    • Understanding the benefits and risks is crucial for optimizing cardiovascular care in ESRD.
    • Statins may offer a potential strategy to mitigate high CVD rates in this vulnerable group.

    Outlook:

    • Further clinical trials are warranted to establish definitive guidelines for statin use in dialysis patients.
    • Expanded utilization of statins could potentially reduce the substantial burden of CVD in ESRD.
    • Personalized treatment approaches may be necessary to maximize benefits and minimize risks.

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Renal Drug Excretion: Overview01:15

    Renal Drug Excretion: Overview

    As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
    A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
    Renal Failure: Dose Adjustments01:11

    Renal Failure: Dose Adjustments

    In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
    Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
    However, dosage adjustments...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Phase I Reactions: Reductive Reactions01:27

    Phase I Reactions: Reductive Reactions

    Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
    Renal Drug Excretion: Tubular Reabsorption01:25

    Renal Drug Excretion: Tubular Reabsorption

    Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...